• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Black Hawk Acquisition Corporation

    11/13/25 2:41:07 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BKHA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Black Hawk Acquisition Corporation

    (Name of Issuer)


    Ordinary Shares, par value $0.0001

    (Title of Class of Securities)


    G1148A101

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G1148A101


    1Names of Reporting Persons

    Kerry Propper
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    240,999.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    240,999.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    240,999.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.8 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Please see note in Item 4(a).


    SCHEDULE 13G

    CUSIP No.
    G1148A101


    1Names of Reporting Persons

    Antonio Ruiz-Gimenez
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    SPAIN
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    240,999.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    240,999.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    240,999.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.8 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Please see note in Item 4(a).


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Black Hawk Acquisition Corporation
    (b)Address of issuer's principal executive offices:

    4125 Blackhawk Plaza Circle, Suite 166 Danville, California 94506
    Item 2. 
    (a)Name of person filing:

    Antonio Ruiz-Gimenez* Kerry Propper*
    (b)Address or principal business office or, if none, residence:

    1 Pennsylvania Plaza, Suite 4810 New York, New York 10119
    (c)Citizenship:

    Antonio Ruiz-Gimenez - Spain Kerry Propper - United States
    (d)Title of class of securities:

    Ordinary Shares, par value $0.0001
    (e)CUSIP No.:

    G1148A101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Antonio Ruiz-Gimenez - 240,999* Kerry Propper - 240,999* *The Ordinary Shares (the "Shares") of Black Hawk Acquisition Corporation (the "Issuer") reported herein are held by (1) one or more private funds managed by ATW SPAC Management LLC ("ATW SPAC"), which has been delegated exclusive authority to vote and/or direct the disposition of certain Shares and (2) a private fund, SZOP Multistrat LP, managed by SZOP Multistrat Management LLC ("SZOP"). SZOP and ATW SPAC are registered investment advisers whose managing members are Kerry Propper and Antonio Ruiz-Gimenez (the "Control Persons"). The percentages reported herein are based upon the 4,153,577 Shares issued and outstanding as disclosed in the Issuer's Form 8-K/A filed with the SEC on July 22, 2025. By virtue of the relationships, the Control Persons may be deemed to have shared voting and dispositive power with respect to the Shares. This report shall not be deemed an admission that the Control Persons or any other person is the beneficial owner of the Shares reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Control Persons disclaims beneficial ownership of the Shares reported herein except to the extent of each of their pecuniary interest, if any, therein.
    (b)Percent of class:

    Antonio Ruiz-Gimenez - 5.8% Kerry Propper - 5.8%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Antonio Ruiz-Gimenez - 0 Kerry Propper - 0

     (ii) Shared power to vote or to direct the vote:

    Antonio Ruiz-Gimenez - 240,999* Kerry Propper - 240,999*

     (iii) Sole power to dispose or to direct the disposition of:

    Antonio Ruiz-Gimenez - 0 Kerry Propper - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Antonio Ruiz-Gimenez - 240,999* Kerry Propper - 240,999*

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Kerry Propper
     
    Signature:/s/ Kerry Propper
    Name/Title:Individually
    Date:11/13/2025
     
    Antonio Ruiz-Gimenez
     
    Signature:/s/ Antonio Ruiz-Gimenez
    Name/Title:Individually
    Date:11/13/2025
    Exhibit Information

    Exhibit I - JOINT FILING STATEMENT

    Get the next $BKHA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BKHA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BKHA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer

    BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles and a proposed de-SPAC acquisition target for Black Hawk Acquisition Corporation (NASDAQ:BKHA, BKHAU, BKHAR)), today announced that its Board of Directors has appointed Michael Tolentino, M.D., an accomplished biotech leader with deep industry experience, as Chief Executive Officer (CEO), effective March 17, 2026. He succeeds Founder and CEO Luo Feng, Ph.D., who has been appointed Chief Scientific Officer. "Dr. Tolentino

    3/18/26 10:42:50 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BKHA
    SEC Filings

    View All

    SEC Form 10-Q filed by Black Hawk Acquisition Corporation

    10-Q - Black Hawk Acquisition Corp (0002000775) (Filer)

    4/20/26 6:23:25 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form NT 10-Q filed by Black Hawk Acquisition Corporation

    NT 10-Q - Black Hawk Acquisition Corp (0002000775) (Filer)

    4/14/26 4:14:17 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Black Hawk Acquisition Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Black Hawk Acquisition Corp (0002000775) (Filer)

    4/1/26 4:56:37 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BKHA
    Leadership Updates

    Live Leadership Updates

    View All

    Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer

    BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles and a proposed de-SPAC acquisition target for Black Hawk Acquisition Corporation (NASDAQ:BKHA, BKHAU, BKHAR)), today announced that its Board of Directors has appointed Michael Tolentino, M.D., an accomplished biotech leader with deep industry experience, as Chief Executive Officer (CEO), effective March 17, 2026. He succeeds Founder and CEO Luo Feng, Ph.D., who has been appointed Chief Scientific Officer. "Dr. Tolentino

    3/18/26 10:42:50 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BKHA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Black Hawk Acquisition Corporation

    SC 13G/A - Black Hawk Acquisition Corp (0002000775) (Subject)

    11/15/24 9:17:26 AM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Black Hawk Acquisition Corporation

    SC 13G - Black Hawk Acquisition Corp (0002000775) (Subject)

    11/14/24 8:39:26 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Black Hawk Acquisition Corporation

    SC 13G - Black Hawk Acquisition Corp (0002000775) (Subject)

    11/14/24 6:13:30 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care